The importance of FLT3 mutational analysis in acute myeloid leukemia

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Activating mutations in FMS-like tyrosine kinase 3 (FLT3), including internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations, are common in patients with acute myeloid leukemia (AML). FLT3-ITD is a negative prognostic factor that remains prognostically relevant even after intensive chemotherapy and/or stem cell transplant. FLT3 testing was historically viewed as being purely prognostic; however, with the advent of FLT3 inhibitors, it will likely be seen as both prognostic and predictive. The multikinase inhibitor midostaurin, in combination with chemotherapy, is the first targeted agent to significantly prolong survival in patients with newly diagnosed FLT3-mutated AML and was recently approved by health authorities. Recently, the European LeukemiaNet recommended FLT3 testing (both TKD and ITD) for all patients with AML, with results required within 3 days. The need for optimized, multigene platform testing incorporating FLT3 mutations will increase as knowledge of interactions between FLT3 and other myeloid-relevant mutations grows.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Nov 23 2017

Fingerprint

Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Mutation
4'-N-benzoylstaurosporine
Combination Drug Therapy
Stem Cells
Transplants
Drug Therapy
Survival
Health

Keywords

  • AML
  • FLT3 testing
  • FLT3 tyrosine kinase inhibitor
  • predictive marker
  • prognostic

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The importance of FLT3 mutational analysis in acute myeloid leukemia. / Patnaik, Mrinal M.

In: Leukemia and Lymphoma, 23.11.2017, p. 1-14.

Research output: Contribution to journalArticle

@article{3bf46b047e3741bcb69f4d3f3f481bd9,
title = "The importance of FLT3 mutational analysis in acute myeloid leukemia",
abstract = "Activating mutations in FMS-like tyrosine kinase 3 (FLT3), including internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations, are common in patients with acute myeloid leukemia (AML). FLT3-ITD is a negative prognostic factor that remains prognostically relevant even after intensive chemotherapy and/or stem cell transplant. FLT3 testing was historically viewed as being purely prognostic; however, with the advent of FLT3 inhibitors, it will likely be seen as both prognostic and predictive. The multikinase inhibitor midostaurin, in combination with chemotherapy, is the first targeted agent to significantly prolong survival in patients with newly diagnosed FLT3-mutated AML and was recently approved by health authorities. Recently, the European LeukemiaNet recommended FLT3 testing (both TKD and ITD) for all patients with AML, with results required within 3 days. The need for optimized, multigene platform testing incorporating FLT3 mutations will increase as knowledge of interactions between FLT3 and other myeloid-relevant mutations grows.",
keywords = "AML, FLT3 testing, FLT3 tyrosine kinase inhibitor, predictive marker, prognostic",
author = "Patnaik, {Mrinal M}",
year = "2017",
month = "11",
day = "23",
doi = "10.1080/10428194.2017.1399312",
language = "English (US)",
pages = "1--14",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - The importance of FLT3 mutational analysis in acute myeloid leukemia

AU - Patnaik, Mrinal M

PY - 2017/11/23

Y1 - 2017/11/23

N2 - Activating mutations in FMS-like tyrosine kinase 3 (FLT3), including internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations, are common in patients with acute myeloid leukemia (AML). FLT3-ITD is a negative prognostic factor that remains prognostically relevant even after intensive chemotherapy and/or stem cell transplant. FLT3 testing was historically viewed as being purely prognostic; however, with the advent of FLT3 inhibitors, it will likely be seen as both prognostic and predictive. The multikinase inhibitor midostaurin, in combination with chemotherapy, is the first targeted agent to significantly prolong survival in patients with newly diagnosed FLT3-mutated AML and was recently approved by health authorities. Recently, the European LeukemiaNet recommended FLT3 testing (both TKD and ITD) for all patients with AML, with results required within 3 days. The need for optimized, multigene platform testing incorporating FLT3 mutations will increase as knowledge of interactions between FLT3 and other myeloid-relevant mutations grows.

AB - Activating mutations in FMS-like tyrosine kinase 3 (FLT3), including internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) mutations, are common in patients with acute myeloid leukemia (AML). FLT3-ITD is a negative prognostic factor that remains prognostically relevant even after intensive chemotherapy and/or stem cell transplant. FLT3 testing was historically viewed as being purely prognostic; however, with the advent of FLT3 inhibitors, it will likely be seen as both prognostic and predictive. The multikinase inhibitor midostaurin, in combination with chemotherapy, is the first targeted agent to significantly prolong survival in patients with newly diagnosed FLT3-mutated AML and was recently approved by health authorities. Recently, the European LeukemiaNet recommended FLT3 testing (both TKD and ITD) for all patients with AML, with results required within 3 days. The need for optimized, multigene platform testing incorporating FLT3 mutations will increase as knowledge of interactions between FLT3 and other myeloid-relevant mutations grows.

KW - AML

KW - FLT3 testing

KW - FLT3 tyrosine kinase inhibitor

KW - predictive marker

KW - prognostic

UR - http://www.scopus.com/inward/record.url?scp=85034668179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034668179&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1399312

DO - 10.1080/10428194.2017.1399312

M3 - Article

C2 - 29164965

AN - SCOPUS:85034668179

SP - 1

EP - 14

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -